<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204473</url>
  </required_header>
  <id_info>
    <org_study_id>TYKM1601101</org_study_id>
    <nct_id>NCT04204473</nct_id>
  </id_info>
  <brief_title>A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation</brief_title>
  <official_title>Phase I, Open-label, Single-arm Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of TY-9591 Tablets in Advanced NSCLC Patients With Epidermal Growth Factor Receptor( EGFR) Positive Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TYK Medicines, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TYK Medicines, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of TY-9591,
      with dose-escalation stage and dose-expansion stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To define the maximum tolerated dose(MTD) and the recommended phase 2 dose (RP2D)

        -  To investigate the pharmacokinetic profile of TY-9591 and its metabolites after single
           then multiple doses of TY-9591 administered orally once daily

        -  To evaluate the anti-cancer activity of TY-9591 in NSCLC patients with EGFR
           mutation(ORR、PFS、DoR、DCR、and CBR)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>First 29 days of dosing</time_frame>
    <description>Incidence of Dose Limiting Toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>1year</time_frame>
    <description>To determine the Maximum Tolerated Dose (MTD) of TY-9591 in subjects with NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>through study completion, an average of 2.5 years</time_frame>
    <description>Recommended Phase 2 dose (RP2D) of TY-9591 in subjects with NSCLC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>pharmacokinetics(PK) blood samples are collected at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12, 24, 48, 72,96,120,144,168 and 192 hours post-dose.</time_frame>
    <description>Cmax of TY-9591 following single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>pharmacokinetics(PK) blood samples are collected at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12, 24, 48, 72,96,120,144,168 and 192 hours post-dose.</time_frame>
    <description>Tmax of TY-9591 following single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve(AUC)</measure>
    <time_frame>pharmacokinetics(PK) blood samples are collected at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12, 24, 48, 72,96,120,144,168 and 192 hours post-dose</time_frame>
    <description>AUC of TY-9591 following single dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>The datas should be evaluated multiple times on Cycle 1 day1,8,15, 21 pre-dose; Cycle 2 day1 (at pre-dose, 0.5,1, 2, 3, 4, 6, 8, 10,12, 24 hours post-dose). Each cycle is 21 days</time_frame>
    <description>Cmax of TY-9591 following multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>The datas should be evaluated multiple times on Cycle 1 day1,8,15, 21 pre-dose; Cycle 2 day1 (at pre-dose, 0.5,1, 2, 3, 4, 6, 8, 10,12, 24 hours post-dose). Each cycle is 21 days</time_frame>
    <description>Cmin of TY-9591 following multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>The datas should be evaluated multiple times on Cycle 1 day1,8,15, 21 pre-dose; Cycle 2 day1 (at pre-dose, 0.5,1, 2, 3, 4, 6, 8, 10,12, 24 hours post-dose). Each cycle is 21 days</time_frame>
    <description>AUC of TY-9591 following multiple dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>10.1 months</time_frame>
    <description>PFS is defined as time from date of first dose of study treatment to date of first documented disease progression or death due to any cause determined by by Investigator assessment in accordance to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>9.7 months</time_frame>
    <description>DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause determined by Investigator assessment in accordance to RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>TY-9591</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Find maximum tolerated dose of TY-9591 given orally. Escalating doses of TY-9591 starting at 20mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TY-9591(10mg,40mg) qd. po</intervention_name>
    <description>Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)</description>
    <arm_group_label>TY-9591</arm_group_label>
    <other_name>TY-9591</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-75years old, male or female.

          2. Histological or cytological confirmation diagnosis of NSCLC

          3. At least one measurable lesion according to Response Evaluation Criteria in Solid
             Tumours (RECIST) version 1.1.

          4. Life expectancy of at least 3 months.

          5. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.

          6. Documentation of disease progression while on previous continuous treatment with
             first-line EGFR TKI; patients must have confirmation of tumor EGFR activating
             mutations (exon 19 del, or exon 21 ) and T790M mutation status

          7. Adequate bone marrow reserve or organ function as demonstrated by any of the following
             laboratory values:

             a.Neutrophils (absolute value) ≥ 1.5×10^9/L; b.Hemoglobin ≥ 90 g/L; c.Platelet ≥
             80×10^9/L; d.Serum total bilirubin ≤ 1.5× ULN（for Patients with Gilbert Syndrome,
             total bilirubin ≤ 3×ULN and bilirubin ≤ 1.5×ULN should be permitted） f. Aspartate
             aminotransferase(AST)、alanine aminotransferase(ALT) ≤ 2.5×ULN; for patients with
             hepatic metastases, AST、ALT ≤ 5×ULN; g. International standardized ratio (INR) &lt; 1.5,
             and activated partial prothrombin time (APTT) &lt; 1.5×ULN;

          8. Female subjects have a negative urine or serum pregnancy.

          9. Provision of signed and dated, written informed consent prior to any study specific
             procedures, sampling and analyses.

        Exclusion Criteria:

          1. Treatment with any of the following:

               1. Treatment with an EGFR TKI within 14 days or about 5x half-life, whichever is the
                  longer, of the first dose of study drug;

               2. Any cytotoxic chemotherapy, investigational agents or anticancer drugs for the
                  treatment from a previous treatment regimen within 4 weeks of the first dose of
                  study treatment;

               3. Major surgery within 4 weeks of the first dose of study treatment;

               4. Radiotherapy with a limited field of radiation within 1 week of the first dose of
                  study treatment, with the exception of patients receiving radiation to more than
                  30% of the bone marrow or with a wide field of radiation that had to be completed
                  within 4 weeks of the first dose of study treatment;

               5. Previously treated by other third-generation epidermal growth factor receptor
                  tyrosine kinase inhibitor(EGFR-TKI) for T790M (for example Osimertinib).

               6. Patients currently receiving (or at least within 1 week prior to receiving the
                  first dose )medications or herbal supplements known to be potent inhibitors or
                  inducers of cytochrome P450 isoenzyme (CYP)3A4.

          2. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria
             for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the
             exception of alopecia and grade 2, prior platinum-therapy related neuropathy.

          3. Spinal cord compression or brain metastases unless asymptomatic.

          4. Dysphagia, or active digestive system diseases or previous significant bowel resection
             or medical conditions potentially affect TY-9591 absorption.

          5. Cardiac function and disease are consistent with the following:

               1. Corrected QT interval(QTc)&gt; 470 milliseconds from 3 electrocardiograms (ECGs);

               2. Any clinically important abnormalities in rhythm;

               3. Any factors that increase the risk of QTc prolongation;

               4. Left ventricular ejection fraction (LVEF) &lt;50%;

          6. Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or
             hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic
             hepatitis b or hepatitis c carriers.

        7 .Previous history of interstitial lung disease(ILD)、drug-induced ILD or radiation
        pneumonitis require steroid treatment, or any evidence of clinically active ILD diseases.

        8. Previous allogeneic bone marrow transplant. 9. Hypersensitivity to TY-9591 or similar
        compounds or excipients. 10.Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baohui Han, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baohui Han, MD</last_name>
    <phone>18930858216</phone>
    <email>18930858216@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baohui Han, MD</last_name>
      <phone>18930858216</phone>
      <email>18930858216@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

